Federal Supply Schedule 36F79718D0566
Award Date 9/15/18
Last Date to Order 9/14/26
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
Pricing Type
Fixed Price with Economic Price Adjustment
Legislative Mandate
Not listed National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed Similar IDVs
- Biogen U.S. Corporation, a pharmaceutical and biotechnology company specializing in neurological disease therapies, was awarded a single-award Blanket Purchase Agreement (BPA) valued at $430,578.10 by the National Acquisition Center, a civilian federal agency, effective December 4, 2023, through October 29, 2025. This BPA, established under the Pharmaceuticals and Drugs General Services Administration (GSA) Schedule (FSS-61-IB), procures Spinraza, a pharmaceutical product indicated for the...
- The U.S. Department of Veterans Affairs (VA) has awarded a Federal Supply Schedule contract (FSS-61-IB) to UCB, Inc., a global biopharmaceutical company, for the procurement of pharmaceutical drugs and related products. The contract has a ceiling value of $625,636,910 and a period of performance through September 14, 2025. Under this contract, UCB, Inc. will supply a variety of pharmaceutical products to the VA, with a focus on drugs used to treat neurology and immunology disorders, such as...
- Biogen U.S. Corporation was awarded a single-award Indefinite Delivery Contract by the Veterans Affairs National Acquisition Center on December 23, 2023, for the supply of ranibizumab (BYOOVIZ) vials. The contract carries a ceiling value of $11.4 million and covers pharmaceutical supply to the Department of Veterans Affairs, Bureau of Prisons, and Indian Health Service. The initial period of performance ran from December 23, 2023, through December 22, 2024, with four one-year option periods...
- Neurocrine Biosciences, Inc. holds a General Services Administration Multiple Award Schedule contract for Pharmaceuticals and Drugs (FSS-61-IB) awarded on April 15, 2018, with an ultimate completion date of August 31, 2026, and a ceiling value of $6,576,000. This Federal Supply Schedule contract enables the Department of Veterans Affairs, specifically Veterans Integrated Service Network 12 and other Veterans Health Administration networks, to procure pharmaceutical products on a recurring basis....
- The Department of Veterans Affairs awarded a multiple-award Federal Supply Schedule contract to Viela Bio, Inc. against the Pharmaceuticals and Drugs schedule for an estimated $12.98 million. This IDV establishes supply of pharmaceutical products to various VA medical centers nationwide through 2022. A single-award Blanket Purchase Agreement against the same FSS schedule was also awarded to Viela Bio for an estimated $4.35 million. This BPA facilitates streamlined delivery of the neuromyelitis...
- This Federal Supply Schedule contract, awarded to Novartis Gene Therapies Inc. (UEI: H1YRZN8TQBC3) on September 15, 2020, establishes a multiple-award indefinite delivery vehicle for the procurement of drugs, pharmaceuticals, and hematology-related products under General Services Administration Schedule 61-IB. The contract carries a ceiling value of $6.0 billion and operates through September 14, 2026. As a non-set-aside award, this contract is available to all qualified vendors meeting the...
- The Federal Supply Schedule (FSS) contract, awarded by the Department of Veterans Affairs (VA) Veterans Integrated Service Network 12, allows the VA to procure drugs, pharmaceuticals, and hematology-related products from Bluebird Bio, Inc. through October 2028. The multiple-award, $300,000 contract under Schedule 65 IB enables the VA to acquire Bluebird Bio's gene therapies and hematology products to treat veterans with rare genetic disorders and blood diseases. Additionally, Bluebird Bio...
- Biocodex, Inc. was awarded a multiple-award Federal Supply Schedule contract under the Pharmaceuticals and Drugs schedule (FSS-61-IB) on May 1, 2020, with a ceiling value of $700,000. This civilian contract, funded through the Veterans Integrated Service Network 12, represents a General Services Administration indefinite delivery vehicle for the supply of pharmaceuticals, drugs, and hematology-related products. No small business set-aside was utilized for this award. The contract extends through...
- This is a Federal Supply Schedule (FSS) contract awarded by the Veterans Integrated Service Network 12 (VISN 12), a civilian federal agency, to Bioxcel Therapeutics, Inc. The contract has a ceiling value of $25,000.00 and a period of performance through February 14, 2023. The contract is for an "Interim Agreement under FSS Schedule 65 I B Drugs, Pharmaceuticals, & Hematology Related Products." This indicates the contract provides for the delivery of pharmaceutical and related...
- Amgen USA Inc. holds a multiple-award Federal Supply Schedule contract (36F79721D0086) valued at $3.37 billion under the General Services Administration's Pharmaceuticals and Drugs schedule (FSS-61-IB), awarded by the Department of Veterans Affairs on February 1, 2021, with completion scheduled for July 31, 2026. This indefinite delivery vehicle authorizes Amgen to supply pharmaceuticals, drugs, and hematology-related products to various federal agencies, including the Veterans Health...
Name | Description | Awardee | Potential Value | AwardDate | LastDateToOrder | Updated At |
|---|---|---|---|---|---|---|
36F79718D0566-36E79719A0008 | Biogen U.s. Corporation | $572.2k | 12/4/18 | 12/3/23 | 11/21/22 | |
36F79718D0566-36E79724A0003 | Biogen U.s. Corporation | $430.6k | 12/4/23 | 10/29/25 | 10/29/25 |
Name | Description | Awardee | Potential Value | AwardDate | CompletionDate | Updated At |
|---|---|---|---|---|---|---|
Delivery Order 36F79718D0566-36C26025F0084 | Biogen U.s. Corporation | $43.5k | 11/13/24 | 2/13/25 | 11/13/24 | |
Delivery Order 36F79718D0566-36C26024F0379 | Biogen U.s. Corporation | $43.5k | 4/24/24 | 6/1/24 | 4/24/24 | |
Delivery Order 36F79718D0566-36C26124N0494 | Biogen U.s. Corporation | $10.9k | 3/13/24 | 4/13/24 | 3/13/24 | |
Delivery Order 36F79718D0566-36C26124N0658 | Biogen U.s. Corporation | $21.7k | 5/16/24 | 5/16/24 | 5/16/24 | |
Delivery Order 36F79718D0566-36C26124N0750 | Biogen U.s. Corporation | $21.7k | 7/2/24 | 8/2/24 | 7/2/24 |